Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Amiodarone-induced thyrotoxicosis (AIT) is a clinical condition that is notoriously difficult to manage; the relative risk of adverse cardiovascular events in these patients compared with euthyroid patients is largely unknown. Objective: We compared the clinical characteristics and major adverse cardiovascular events (MACE) in AIT and euthyroid patients. Method: Patients at a tertiary referral center who had been prescribed amiodarone for at least 3 months were retrospectively analyzed. Baseline clinical characteristics, laboratory parameters, and outcome events were evaluated. MACE was defined as cardiovascular mortality, myocardial infarction, stroke and heart failure, or ventricular arrhythmias that required hospitalization. Results: A total of 354 patients (61.8 ± 14.1 yr; 64.7% male) with a mean follow-up of 48.6 ± 26.7 months were studied. AIT, euthyroid status, and amiodarone-induced hypothyroidism were identified in 57 (16.1%), 224 (63.3%), and 73 (20.6%) patients, respectively. No differences in baseline clinical characteristics were observed between AIT and euthyroid patients. Nonetheless AIT patients demonstrated a higher MACE rate (31.6 vs. 10.7%, P < 0.01), mostly driven by a higher rate of ventricular arrhythmias that required admission (7.0 vs. 1.3%, P = 0.03). Cox-regression multivariate analysis revealed that AIT (hazard ratio 2.68; confidence interval 1.53–4.68; P < 0.01) and left ventricular ejection fraction less than 45% (hazard ratio 2.52; confidence interval 1.43–4.42; P < 0.01) were independent predictors of MACE. Conclusion: In patients prescribed long-term amiodarone therapy, occurrence of AIT is associated with a 2.7-fold increased risk of MACE. Regular and close biochemical surveillance is thus advisable to identify and treat this high-risk group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Successful Treatment of Amiodarone-Induced Thyrotoxicosis
Osman, F., Franklyn, J. A., Sheppard, M. C., & Gammage, M. D. (2002) · Circulation · doi:10.1161/circ.105.11.1275 · Cited by 96
Cited by
MECHANISMS IN ENDOCRINOLOGY: Heart failure and thyroid dysfunction
Biondi, B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0627 · Cited by 291
Bartalena, L., Bogazzi, F., Chiovato, L., Hubalewska-Dydejczyk, A., Links, T. P., & Vanderpump, M. (2018) · European Thyroid Journal · doi:10.1159/000486957 · Cited by 264
Franklyn, J. A., & Boelaert, K. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60782-4 · Cited by 262
Effects of amiodarone therapy on thyroid function
Cohen-Lehman, J., Dahl, P., Danzi, S., & Klein, I. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.225 · Cited by 157
“Patients who develop both types of AIT have an increased risk of major adverse cardiovascular events, including myocardial infarction, stroke and ventricular arrhythmias, compared with euthyroid amiodarone-treated individuals”
BackgroundEskes, S. A., & Wiersinga, W. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.07.001 · Cited by 148
Metadata
- Authors
- Yiu, K.-H., Jim, M.-H., Siu, C.-W., Lee, C.-H., Yuen, M., Mok, M., Shea, Y.-F., Fan, K., Tse, H.-F., & Chow, W.-H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-01-01
- Volume
- 94
- Issue
- 1
- Pages
- 109-114
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2053066897
- Cited by
- 95
- References
- 2
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome. https://app.cochat.ai/papers/10.1210/jc.2008-1907
- The paper
- Yiu, K.-H., Jim, M.-H., Siu, C.-W., Lee, C.-H., Yuen, M., Mok, M., Shea, Y.-F., Fan, K., Tse, H.-F., & Chow, W.-H. (2009). Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-1907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.